Johnson & Johnson

• Amgen shares dropped despite beating third-quarter revenue and earnings consensus estimates. • Legacy franchises face accelerating sales declines from biosimilar competition and patent expirations. • Management flagged rising fourth-quarter operating expenditures and increased capital investment requirements.

• Eli Lilly shares declined due to valuation sensitivity and competitive metabolic dynamics. • Institutional profit-taking and macroeconomic cross-asset flows exacerbated the recent pullback. • The company maintains strong fundamentals, with $65.18 billion in annual revenue.

• Gilead shares declined due to institutional profit-taking and technical consolidation after earnings. • Acquired research and development charges created headwinds for reported GAAP profitability. • Analysts maintain a buy rating with an average price target of $171.76.

• AbbVie exceeded consensus estimates and raised its full-year guidance. • Skyrizi and Rinvoq drove strong double-digit sales expansion. • Multiple Wall Street firms raised their price targets.

• Merck raised full-year guidance following strong financial results and global demand. • Late-stage pipeline progress reinforced confidence in the company's growth strategy. • Analysts assigned an average price target of $157.01 with Buy ratings.

• Johnson & Johnson reported positive clinical trial updates in MedTech and oncology portfolios. • The company exceeded quarterly earnings forecasts and reaffirmed its full-year earnings guidance. • Institutional stakeholders increased their positions amid favorable analyst ratings and technical buy signals.